Helus Pharma Inc. Common Stock
HELP
66 hedge funds and large institutions have $2.84M invested in Helus Pharma Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 13 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
2.57% less ownership
Funds ownership: 6.46% → 3.89% (-2.6%)
6% less funds holding
Funds holding: 70 → 66 (-4)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
18% less capital invested
Capital invested by funds: $3.45M → $2.84M (-$612K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$257K |
| 2 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$213K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$107K |
| 4 |
Barclays
London,
United Kingdom
|
+$25.7K |
| 5 |
WLPWM
Walled Lake Planning & Wealth Management
Winnetka,
Illinois
|
+$24.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.65M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$42.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$30.6K |
| 4 |
Millennium Management
New York
|
-$15K |
| 5 |
T
TCWP
Beachwood,
Ohio
|
-$13.6K |
HELP Hedge Fund Activity: Q1 2023 in Review
66 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q1 2023, worth a combined $2.84M — down 18% from $3.45M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HELP and 11 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was AdvisorShares Investments, adding an estimated $257K. The largest seller was OrbiMed, exiting entirely with an estimated $1.65M sold.
- 66 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q1 2023, down from 70 in Q4 2022.
- Funds reported $2.84M of Helus Pharma Inc. Common Stock stock for Q1 2023, down 18% quarter-over-quarter.
- 11 funds opened new Helus Pharma Inc. Common Stock positions in Q1 2023 and 13 closed out, a net change of -2 holders.
- The largest Helus Pharma Inc. Common Stock buyer in Q1 2023 was AdvisorShares Investments, an estimated $257K added.
- The largest Helus Pharma Inc. Common Stock seller in Q1 2023 was OrbiMed, an estimated $1.65M sold.
Based on aggregated 13F filings for Q1 2023.